In:
Journal of the American Heart Association, Ovid Technologies (Wolters Kluwer Health), Vol. 5, No. 11 ( 2016-10-26)
Abstract:
We previously identified peritoneal B1a cells that secrete natural IgM as a key atheroprotective B cell subset. However, the molecules that activate atheroprotective B1a cells are unknown. Here, we investigated whether Toll‐like receptors (TLRs) TLR 2, TLR 4, and TLR 9 expressed by B1a cells are required for IgM‐mediated atheroprotection. Methods and Results We adoptively transferred B1a cells from wild‐type mice or from mice deficient in TLR 2, TLR 4, TLR 9, or myeloid differentiation primary response 88 (MyD88) into ApoE −/− mice depleted of peritoneal B1a cells by splenectomy and fed a high‐fat diet for 8 weeks. Elevations in plasma total, anti‐oxLDL (oxidized low‐density lipoprotein), anti‐leukocyte, anti‐ CD 3, anti‐ CD 8, and anti‐ CD 4 IgMs in atherosclerotic mice required B1a cells expressing TLR 4 and MyD88, indicating a critical role for TLR 4‐MyD88 signaling for IgM secretion. Suppression of atherosclerosis was also critically dependent on B1a cells expressing TLR 4‐MyD88. Atherosclerosis suppression was associated not only with reductions in lesion apoptotic cells, necrotic cores, and ox LDL , but also with reduced lesion CD 4 + and CD 8 + T cells. Transforming growth factor beta 1 ( TGF ‐β1) expression, including macrophages expressing TGF ‐β1, was increased, consistent with increased IgM‐mediated phagocytosis of apoptotic cells by macrophages. Reductions in lesion inflammatory cytokines tumor necrosis factor alpha ( TNF ‐α), interleukin ( IL) 1β, and IL ‐18 were consistent with augmented TGF ‐β1 expression. Conclusions TLR 4‐MyD88 expression on B1a cells is critical for their IgM‐dependent atheroprotection that not only reduced lesion apoptotic cells and necrotic cores, but also decreased CD 4 and CD 8 T‐cell infiltrates and augmented TGF ‐β1 expression accompanied by reduced lesion inflammatory cytokines TNF ‐α, IL ‐1β, and IL ‐18.
Type of Medium:
Online Resource
ISSN:
2047-9980
DOI:
10.1161/JAHA.115.002947
Language:
English
Publisher:
Ovid Technologies (Wolters Kluwer Health)
Publication Date:
2016
detail.hit.zdb_id:
2653953-6
Bookmarklink